New Jersey Institute of Technology’s efforts to nurture and support businesses led by African-Americans are being recognized by a caucus of county commissioners.

The caucus, New Jersey Nineteen (NJ19), comprised of Black county commissioners, bestowed an African-American Business Champion Award to Joel S. Bloom, NJIT’s president since 2011.



Central to the university’s support for Black businesses is VentureLink, the business incubator housed under its New Jersey Innovation Institute. 

Dr. Haro Hartounian, SVP and general manager of BioCentriq, was recognized as a Sector Star in ROI-NJ's annual list of influencers in the health care industry.

Highlanders who want to start a business will soon have access to a $75,000 seed investment from the university's new Venture Fund as part of a 10-year, $6.75 million commitment funded by the NJIT endowment.

New Jersey Institute of Technology has been named Member of the Year by the New Jersey Business and Industry Association (NJBIA) in its New Jersey Business magazine.

The award recognizes efforts to improve the state’s business climate.

Minorities and underserved residents in Newark will soon have unique opportunities to establish high-tech businesses, based on three new programs from the VentureLink arm of NJIT's New Jersey Innovation Institute.

Two leaders at New Jersey Institute of Technology made NJBIZ’s list of the 2021 Education Power 50: President Joel S. Bloom and Simon Nynes, CEO of NJIT’s New Jersey Innovation Institute (NJII).

The annual list recognizes the most impactful and influential educational leaders in New Jersey.  

Three leaders at New Jersey Institute of Technology are featured in ROI-NJ’s annual recognition of education influencers, including President Joel S. Bloom, who was named Influencer of the Year.

A computer science major at New Jersey Institute of Technology has earned the top prize in a statewide collegiate competition that judges pitches for innovative business ideas.

The student, Yashwee Kothari ’22, pitched a mobile application for tracking the symptoms of people recovering from traumatic brain injuries – an idea she has been developing since high school. 

Tevogen Bio announces partnership with BioCentriq, New Jersey Innovation Institute’s pioneering cell and gene therapy center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.

Under the partnership, experts from both entities will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will utilize the processes and technology required to ensure that all quality standards are met in the large scale manufacturing of Tevogen’s clinical grade, allogeneic T-cell therapy.

New Jersey Institute of Technology President Joel S. Bloom and four members of a key university board made the NJBIZ 2021 Power 100 list of the biggest players in the state’s economy.